<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01101412</url>
  </required_header>
  <id_info>
    <org_study_id>2009-0237</org_study_id>
    <secondary_id>MDA-2009-0237</secondary_id>
    <secondary_id>CDR0000668850</secondary_id>
    <nct_id>NCT01101412</nct_id>
  </id_info>
  <brief_title>Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies</brief_title>
  <official_title>Multi-Center, Prospective, Randomized, Double-Blinded, Controlled Clinical Trial to Evaluate the Safety and Effectiveness of an Antimicrobial Catheter Lock Solution in Maintaining Catheter Patency and Preventing Catheter Related Blood Stream Infections (CRBSI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Antimicrobial solution comprising trimethoprim-sulfamethoxazole, edetate calcium
      disodium, and ethanol may help prevent blockages and infections from forming in patients with
      central venous access catheters or peripheral venous catheters.

      PURPOSE: This randomized trial is studying an antimicrobial solution or saline solution in
      maintaining catheter patency and preventing catheter-related blood infections in patients
      with malignancies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  To evaluate the safety of antimicrobial catheter lock solution comprising
           trimethoprim-sulfamethoxazole, edetate calcium disodium (EDTA), and ethanol versus
           saline solution in patients with malignancies.

        -  To compare the efficacy of this lock solution versus saline solution in maintaining
           catheter patency in these patients.

        -  To demonstrate the superiority of this lock solution in preventing or reducing the
           incidence of catheter-related bloodstream infections in patients with long-term
           indwelling catheters.

      OUTLINE: This is a multicenter study. Patients are stratified according to clinical site and
      randomized to 1 of 2 intervention arms.

        -  Arm I: Patients receive antimicrobial solution into the central or peripheral venous
           catheter (CVC or PVC) once daily for 90 days. Catheter dwell time is 1-24 hours. The
           catheter is then flushed through before any drug infusion or blood aspiration.

        -  Arm II: Patients receive saline solution into the CVC or PVC once daily for 90 days.
           Catheter dwell time is 1-24 hours. The catheter is then flushed through before any drug
           infusion or blood aspiration.

      After completion of study, patients are followed up at 10 days.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study was not opened.
  </why_stopped>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of occlusion as defined by the inability to infuse or withdraw 3 cc of saline from the catheter</measure>
    <time_frame>60 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to development of a catheter-related bloodstream infections during the period of lock therapy administration</measure>
    <time_frame>60 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>60 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Chronic Myeloproliferative Disorders</condition>
  <condition>Infection</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Lymphoproliferative Disorder</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myelodysplastic/Myeloproliferative Neoplasms</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Arm I: Antimicrobial Solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Antimicrobial solution into central or peripheral venous catheter (CVC or PVC) once daily for 90 days. Catheter dwell time is 1-24 hours. The catheter is then flushed through before any drug infusion or blood aspiration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II: Saline Solution</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Saline solution into CVC or PVC once daily for 90 days. Catheter dwell time is 1-24 hours. The catheter is then flushed through before any drug infusion or blood aspiration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Edetate Calcium Disodium</intervention_name>
    <description>Given through CVC or PVC.</description>
    <arm_group_label>Arm I: Antimicrobial Solution</arm_group_label>
    <other_name>Calcium Disodium Versenate</other_name>
    <other_name>Calcium EDTA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ethanol</intervention_name>
    <description>Given through CVC or PVC</description>
    <arm_group_label>Arm I: Antimicrobial Solution</arm_group_label>
    <other_name>Ethyl Alcohol</other_name>
    <other_name>Ehtyol</other_name>
    <other_name>Ethamolin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trimethoprim-sulfamethoxazole</intervention_name>
    <description>Given through CVC or PVC</description>
    <arm_group_label>Arm I: Antimicrobial Solution</arm_group_label>
    <other_name>Bactrim</other_name>
    <other_name>Trimethoprim</other_name>
    <other_name>sulfamethoxazole</other_name>
    <other_name>Bactrim DS</other_name>
    <other_name>Cotrim DS</other_name>
    <other_name>Septra</other_name>
    <other_name>Sulfatrim DS</other_name>
    <other_name>Trisulfam</other_name>
    <other_name>Uroplus DS</other_name>
    <other_name>Uroplus SS</other_name>
    <other_name>Co-trimoxazole</other_name>
    <other_name>SMX-TMP</other_name>
    <other_name>TMP-SMX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hypertonic Saline</intervention_name>
    <description>Given through CVC or PVC</description>
    <arm_group_label>Arm II: Saline Solution</arm_group_label>
    <other_name>Saline</other_name>
    <other_name>Saline Solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of a malignancy

          -  Indwelling catheter (central or peripheral) with external lumen(s) that has been in
             place for ≤ 7 days

               -  Inpatients must have each lumen of the catheter able to be locked with the study
                  solution uninterruptedly for a minimum of one hour per day

               -  Outpatients must agree to flush and relock the catheter each day

        PATIENT CHARACTERISTICS:

          -  Willing and able to follow the instructions required to complete the study

          -  No local or systemic infection as defined by the evidence of fever (e.g., body
             temperature ≥ 38.0 degrees C) within 24 hours including any of the following:

               -  White Blood Count (WBC) ≥ 12,000/mm³ or ≤ 4,000/mm³ OR with a differential count
                  showing ≥ 10% bands

               -  Tachycardia defined as pulse rate ≥ 100 bpm

               -  Tachypnea defined as respiratory rate &gt; 20 breaths/minute

               -  Hypotension defined as systolic blood pressure (BP) ≤ 90 mm Hg

               -  Signs and symptoms of localized catheter-related infection (e.g., tenderness
                  and/or pain, erythema, swelling, or purulent exudate within 2 cm of entry site)

          -  No occluded (partially or totally) catheter defined as inability to either withdraw
             blood or instill 3 cc of fluid without resistance through any catheter lumen

          -  No known alcohol dehydrogenase deficiency

          -  No known history of allergic reaction to ethanol, trimethoprim (including
             trimethoprim/sulfamethoxazole), or any other components within the lock solution
             formulation

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  No renal failure or creatinine level ≥ 2.0 mg/dL

          -  No known heart failure or ejection fraction ≤ 25%

          -  No alcohol dependency

        PRIOR CONCURRENT THERAPY:

          -  Concurrent investigational chemotherapy agents allowed

               -  No concurrent non-chemotherapy investigational protocols

          -  Not requiring multiple central venous catheters

               -  Multiple lumens in a single catheter allowed

          -  No catheter coated or impregnated with heparin or antimicrobial or antiseptic agent

          -  No concurrent routine treatment of the underlying disease that will interfere with the
             lock solution

          -  No concurrent disulfiram or metronidazole
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Chaftari, MD</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jorge Cortes, MD</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Official Website</description>
  </link>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 9, 2010</study_first_submitted>
  <study_first_submitted_qc>April 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2010</study_first_posted>
  <last_update_submitted>February 13, 2013</last_update_submitted>
  <last_update_submitted_qc>February 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>infection</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>acute undifferentiated leukemia</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>atypical chronic myeloid leukemia, BCR-ABL negative</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>mast cell leukemia</keyword>
  <keyword>meningeal chronic myelogenous leukemia</keyword>
  <keyword>progressive hairy cell leukemia, initial treatment</keyword>
  <keyword>prolymphocytic leukemia</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>refractory hairy cell leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>stage 0 chronic lymphocytic leukemia</keyword>
  <keyword>stage I adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage I chronic lymphocytic leukemia</keyword>
  <keyword>stage II adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage II chronic lymphocytic leukemia</keyword>
  <keyword>stage III adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage III chronic lymphocytic leukemia</keyword>
  <keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage IV chronic lymphocytic leukemia</keyword>
  <keyword>T-cell large granular lymphocyte leukemia</keyword>
  <keyword>untreated adult acute lymphoblastic leukemia</keyword>
  <keyword>untreated adult acute myeloid leukemia</keyword>
  <keyword>untreated hairy cell leukemia</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>stage I adult Hodgkin lymphoma</keyword>
  <keyword>stage II adult Hodgkin lymphoma</keyword>
  <keyword>stage III adult Hodgkin lymphoma</keyword>
  <keyword>stage IV adult Hodgkin lymphoma</keyword>
  <keyword>anaplastic large cell lymphoma</keyword>
  <keyword>angioimmunoblastic T-cell lymphoma</keyword>
  <keyword>cutaneous B-cell non-Hodgkin lymphoma</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage I cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage II cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage I mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage II mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
  <keyword>adult grade III lymphomatoid granulomatosis</keyword>
  <keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
  <keyword>Waldenstrom macroglobulinemia</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>contiguous stage II adult Burkitt lymphoma</keyword>
  <keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
  <keyword>contiguous stage II adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>contiguous stage II adult immunoblastic large cell lymphoma</keyword>
  <keyword>contiguous stage II adult lymphoblastic lymphoma</keyword>
  <keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>contiguous stage II mantle cell lymphoma</keyword>
  <keyword>contiguous stage II marginal zone lymphoma</keyword>
  <keyword>contiguous stage II small lymphocytic lymphoma</keyword>
  <keyword>stage I adult Burkitt lymphoma</keyword>
  <keyword>stage I adult diffuse large cell lymphoma</keyword>
  <keyword>stage I adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage I adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage I adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage I adult lymphoblastic lymphoma</keyword>
  <keyword>stage I grade 1 follicular lymphoma</keyword>
  <keyword>stage I grade 2 follicular lymphoma</keyword>
  <keyword>stage I grade 3 follicular lymphoma</keyword>
  <keyword>stage I mantle cell lymphoma</keyword>
  <keyword>stage I marginal zone lymphoma</keyword>
  <keyword>stage I small lymphocytic lymphoma</keyword>
  <keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
  <keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II mantle cell lymphoma</keyword>
  <keyword>noncontiguous stage II marginal zone lymphoma</keyword>
  <keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
  <keyword>stage III adult Burkitt lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage III adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage III adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage III adult lymphoblastic lymphoma</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage III marginal zone lymphoma</keyword>
  <keyword>stage III small lymphocytic lymphoma</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>intraocular lymphoma</keyword>
  <keyword>post-transplant lymphoproliferative disorder</keyword>
  <keyword>chronic eosinophilic leukemia</keyword>
  <keyword>chronic neutrophilic leukemia</keyword>
  <keyword>primary myelofibrosis</keyword>
  <keyword>essential thrombocythemia</keyword>
  <keyword>polycythemia vera</keyword>
  <keyword>extramedullary plasmacytoma</keyword>
  <keyword>isolated plasmacytoma of bone</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>primary systemic amyloidosis</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>myelodysplastic/myeloproliferative neoplasm, unclassifiable</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Disease</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Lymphoproliferative Disorders</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Anti-Infective Agents</mesh_term>
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Trimethoprim</mesh_term>
    <mesh_term>Sulfamethoxazole</mesh_term>
    <mesh_term>Trimethoprim, Sulfamethoxazole Drug Combination</mesh_term>
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Pentetic Acid</mesh_term>
    <mesh_term>Edetic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

